Fourth Year Pharm. D: SUMMER - 2019 SUBJECT: BIOPHARMACEUTICS AND PHARMACOKINETICS

02.00 P.M. TO 05.00 PM Day: Friday Time: 19/04/2019 Date: S-2019-4521 Max. Marks: 70 N.B: Q. No. 1 and Q. No. 5 are COMPULSORY. Out of the remaining attempt ANY 1) **TWO** questions from each section. Figures to the right indicate FULL marks. 2) Answer to the both sections should be written in SEPARATE answer books. 3) **SECTION - I** Q.1 A) Attempt ANY FOUR of the following: (08)Explain the influence of gastric emptying on drug absorption. ii) Enlist the different steps and reactions of biotransformation. iii) Define total clearance and renal clearance. Give their equations. Explain drug related factors affecting protein binding. iv) Name the specialized barriers to distribution of drug. v) vi) Differentiate between passive and active transport mechanism. B) Explain the pre systemic metabolism (03)**Q.2** Explain in details the theories of dissolution. (12)Q.3 Explain Phase I and Phase II metabolic reactions with suitable examples. a) (07)b) Give an account of physicochemical factors influencing drug distribution. (05)Q.4 Write short notes on ANY THREE of the following: (12)Concept of renal clearance a) pH-partition hypothesis b) Significance of protein binding c) Volume of distribution d) **SECTION - II** Attempt ANY FOUR of the following: Q.5 A)(08)What is AUC and trapezoidal rule? i) Enlist the pharmacokinetic parameters. ii) What is non-linear pharmacokinetics? iii) What is zero order kinetics? iv) What are the objectives of bioavailability studies? v) vi) Define drug effect and drug potency. What are the various approaches to quantitative study of kinetic process of (03) B) drug disposition? Derive the equation to obtain the pharmacokinetic parameters for i.v. loading (12) **Q.6** dose followed by i.v. infusion according to one compartment open model. Differentiate between compartment modeling and physiological modeling. (07)Q.7 aElaborate on the study designs employed to establish bioequivalence. (05)b) Write short notes on **ANY THREE** of the following: (12)Q.8 Sigma minus method a) Method of residuals b) Methods of enhancement of bioavailability c) Pharmacokinetic modeling d)